Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Brown Capital Management International All Company Fund 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Brown Capital Management International All Company Fund)

Primary Source Intelligence • Q2 2024 Letter Analysis

Brown Capital Management International All Company Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Brown Capital Management International All Company Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD-2.02%

Annualized+9.55%

Digest Analysis

Quick Take

"Hurt by Carl Zeiss Meditec's 43% drop on guidance cuts. Novo Nordisk's GLP-1 success and AJ Bell's strong earnings provided positive contributions."

Executive Summary

Brown Capital Management's International All Company Fund returned -2.02% in Q2 2024, underperforming benchmarks due to significant detractors including Carl Zeiss Meditec which fell 43% after cutting guidance. The fund follows an Exceptional Growth Company philosophy, seeking businesses with sustainable competitive advantages and long-term growth potential. Key contributors included Novo Nordisk, benefiting from strong GLP-1 drug performance with Ozempic and Wegovy representing 57% of revenue, and AJ Bell which gained 27% on strong earnings. The team added Camtek, an Israeli semiconductor inspection equipment maker, after extensive 15-month research process. The 42-holding portfolio spans 18 countries with 12 names overlapping the Small Company strategy. Election uncertainty across 64 countries including France created market volatility, while interest rates pressured some holdings. The expanded research team collaboration with the Mid Company Team is enhancing the investment process. Management remains optimistic about the strategy's future given the quality of portfolio companies and their ability to adapt to changing conditions.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

The fund demonstrates high conviction through concentrated research (15-month process for Camtek), specific position sizing discussions, and detailed thesis explanations for major holdings. The 42-position portfolio with named holdings and clear investment rationale indicates strong conviction, though the diversified nature prevents a higher score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges election uncertainty and macroeconomic headwinds but maintains a constructive view on the long-term opportunity set. They express excitement about the future of the strategy and believe skilled management teams can adapt to changes, indicating mild optimism despite near-term challenges.

Risk Appetite

15%

DefensiveAggressive

Defensive (15%)

The portfolio remains fully invested with 42 holdings across 18 countries, adding one new position (Camtek) while eliminating one (Ocado). The positioning suggests a selective but committed approach to risk, maintaining exposure while being disciplined about position quality.

Capital Deployment

0%

De-riskingDeploying

De-risking (0%)

The fund added one new position (Camtek) and eliminated one (Ocado Group), representing capital rotation rather than net deployment. No cash level changes or significant scaling of positions were mentioned, indicating neutral capital deployment activity.

Forward Guidance

20%

CautiousExpansionary

Cautious (20%)

The manager expresses excitement about the future strategy with expanded team collaboration and describes being thrilled to own new addition Camtek. However, they are monitoring Carl Zeiss closely and acknowledge short-term concerns, indicating selective optimism in deployment.

Language Signal

30%

BearishBullish

Bearish (30%)

The letter contains more positive language around opportunities, excitement about holdings like Novo Nordisk and Camtek, and optimism about the expanded research process. While risks are acknowledged, the overall tone emphasizes growth potential and long-term positioning.

Perceived Risk

45%

Low RiskElevated

Moderate Risk (45%)

The manager acknowledges election uncertainty across 64 countries, interest rate pressures affecting customer investment decisions, and China economic slowdown. However, these risks are discussed as manageable challenges rather than systemic threats, with confidence in portfolio companies' ability to adapt.

Opportunity Density

65%

ScarceAbundant

Abundant (65%)

The manager describes a vast opportunity set starting with 50,000 international companies, narrowing to 800 after screens. The successful addition of Camtek after extensive research and excitement about the expanded team's capabilities suggests good opportunity availability, though selectivity is emphasized.

Time Horizon

75%

Short-TermLong-Term

Decade+ (75%)

The strategy explicitly focuses on holding companies for several years or even decades as they compound revenue growth. The 15-month research process for Camtek and decade-plus holding period for Novo Nordisk demonstrate a long-term investment approach with patience for thesis realization.